Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Sanofi B.V.

Home Clinical Trial Sponsors and OrganizationsSanofi B.V.

Sanofi B.V.

Paasheuvelweg 25, Amsterdam, Noord-Holland, Netherlands

Also known as:

genzyme europe

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

12

2 active

Approvals

53

Total approvals

Agencies

3

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 3

7

58.3%

Phase 2

3

25.0%

Trial Status Distribution

Active, not recruiting

1

8.3%

Completed

3

25.0%

Not yet recruiting

1

8.3%

Recruiting

7

58.3%

Clinical Trials

Trials sponsored by this organization (12)

SUMMIT Extension Study

Active, not recruiting

Aug 2011142 participants

A Study of Eliglustat Tartrate (Genz-112638) in Patients with Gaucher Disease to Evaluate Once Daily Versus Twice Daily Dosing (EDGE)

Apr 2011234 participants

Prospective, multicenter, double-blind, randomized, cross-over study to evaluate efficacy and safety of sevelamer in the treatment of dyslipidemia in children with persisting proteinuria

May 200620 participants

A phase 2/3, multicenter, randomized, double-blinded, placebo-controlled, repeatdose study to evaluate the efficacy, safety, pharmacodynamics, and pharmacokinetics of olipudase alfa in patients with acid sphingomyelinase deficiency

ong-term extension safety and efficacy study of SAR442168 in participants with relapsing multiple sclerosis.

Randomized, double-blind, placebo-controlled, parallel-group Phase 3 study to evaluate the efficacy, safety, and tolerability of SAR440340/REGN3500/itepekimab (anti-IL-33 mAb) in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD)

10 participants

A Phase 2, multicenter, open-label, non-randomized, proof-of-concept study evaluating the efficacy, safety, and tolerability of SAR445088 (previously BIVV020) in adults with chronic inflammatory demyelinating polyneuropathy (CIDP)

A Phase 3, randomized, double-blind efficacy and safety study comparing SAR442168 to teriflunomide (Aubagio®) in participants with relapsing forms of multiple sclerosis.

Not yet recruiting

Page 1 of 2

Approvals

Approvals by Agency

NMPA

National Medical Products Administration

13

Approvals

EMA

European Medicines Agency

23

Approvals

CIMA_AEMPS

Spanish Agency for Medicines and Medical Devices

17

Approvals

Recent Approvals

WAYRILZ 400 MG COMPRIMIDOS RECUBIERTOS CON PELICULA

Alglucosidase Alfa for Injection

Rabbit Anti-human Thymocyte Immunoglobulin

Rabbit Anti-human Thymocyte Immunoglobulin

News

No news articles found

On this page

Overview
Clinical Trials12
Approvals53
News

Back to Organizations